HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

Efficacy Results From CONTEXT

A total of 320 (315 treated) PI-experienced HIV+ patients experiencing virologic failure (plasma HIV-1 RNA viral load of ?1,000 copies/mL) were enrolled in the CONTEXT study. Forty percent of study participants had prior treatment experience with two or more PIs, 74 percent had experience with 3 or more nucleoside reverse transcriptase inhibitors (NRTIs), and 57 percent had received prior therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Patients were randomized to receive either 1400 mg of 908 QD combined with low dose ritonavir (200 mg QD) (n=105), 700 mg of 908 combined with 100 mg ritonavir BID (n=107), or 400 mg lopinavir/100 mg ritonavir BID (n=103). All three groups took the medications in combination with two active NRTIs. Baseline vRNA (median 4.14 log10 copies/mL) and CD4+ cell counts (median 263 cells/mm3 ) were similar among the treatment arms.

By intent-to-treat analysis at 24 weeks, the mean AAUCMB (log10 c/mL) was -1.48 for patients on 908/r QD, -1.50 for those on 908/r BID and -1.66 for those taking LPV/r BID, according to DeJesus. Positive antiviral responses were seen with both the 908/r and LPV/r regimens, with 48 percent, 42 percent and 40 percent achieving <50 c/mL responses in the LPV/r, 908/r QD and 908/r BID arms, respectively. The median change from baseline in CD4 cells/mm3 was 72 for 908/r QD, 62 for 908/r BID and 63 for LPV/r BID.

Safety Results from CONTEXT

In the CONTEXT trial, the incidence of drug-related adverse events (AEs) of at least moderate severity was low, occurring in 19 percent of patients on 908/r QD (n=20), 35 percent on 908/r BID (n=37) and 34 percent on LPV/r BID (n=35). The most common AEs were diarrhea (5 percent, 10 percent and 8 percent, respectively) and nausea (4 percent, 3 percent and 9 percent, respectively). Additionally, mo
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... SAN DIEGO , Jan. 17, 2017 /PRNewswire/ ... Diego School of Medicine and St. Boniface Hospital ... treatments for peripheral neuropathy, an unmet health need ... in the Journal of Clinical Investigation, their results ... properties that prevent and reverse neuronal injury in ...
(Date:1/17/2017)... 2017 Noom Inc. , the ... to offer fully Spanish behavior change programs that ... diabetes prevention and healthy weight management programs ... lifestyle interventions among Hispanic Americans who are at ... food database, program-specific curriculum content and program features ...
(Date:1/17/2017)... , ... January 17, 2017 ... ... surgeons at the 2016 annual meeting of the North American Spine Society ... for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a leading ... a collaboration with the Heidelberg University Hospital and the German Cancer Research Center ... the company’s successful launch of its CATS (Capture and Amplification by Tailing ...
Breaking Biology Technology:
Cached News: